Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer

Outcomes Comparison of TAMIS-TME Versus Transanal Minimally Invasive Locoregional Resection for T2 Low Rectal Cancer: an Open Label Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02488577

Acronym

TAMIS

Enrollment

Registered

2015-07-02

Start date

2015-06-30

Completion date

2019-10-31

Last updated

2018-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Rectal Cancer

Brief summary

Cases with stage T2 N0 low rectal cancer will undergo either Transanal minimally invasive total mesorectal excision or transanal minimally invasive locoregional resection.

Interventions

PROCEDURETransanal minimally invasive total mesorectal excision

PROCEDUREtransanal minimally invasive locoregional resection

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* T2 N0 low rectal cancer

Exclusion criteria

* patients unfit for laparoscopic resection * Unwilling to share in the study

Design outcomes

Primary

Measure	Time frame	Description
Overall percent of postoperative complications.	30 days	the over all percentage of Postoperative complications concerning Pelvis abscess, anastomosis disruption, bleeding, Fistula and continence function.

Secondary

Measure	Time frame	Description
Hospital stay	30 days	Number of Days starting from the admission till discharge
Recurrence.	2 years	number of local and distant recurrence

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026